Dr. Reddy's CEO G V Prasad also said the company is in the process of shifting some of the products to other plants in the wake of warning letters.
"We have instituted corrective actions to assess the 483 observations received earlier for these sites. The recent letter underscores the need for us to reevaluate the work done in the light of the observations (made by the FDA) and continue to implement the process ...
The country's second largest drug maker last week said it received a warning letter from the US drug regulator relating to two of its Active Pharma Ingredients (API) manufacturing plants and a Formulation plant located in Andhra Pradesh and Telangana.
DRL shares today stumbled by 3.44 per cent over previous close to Rs 3,504.60 on BSE.
Also Read
The stock fell nearly 17 per cent after the news of warning letters came to light.
The warning letter followed the earlier inspections of these sites by the agency in November 2014, January 2015 and February 2015 respectively.